Kornimate/medical-research-clean huggingface dataset:
high risk adult t-cell leukemia/lymphoma (atll-hr) and allogeneic transplant

Conditions: T-cell Lymphoma; Leukaemia

Summary: patients are recruited at diagnosis or at relapse of atll-hr in french caribbean islands and guyana. they all receive zidovudine and pegylated interferon (zpi). for patients younger than 65 years old, an allogeneic donor is searching out. patients included at relapse and with lymphoma clinico-biological subtype also receive chemotherapy (ct). responses are assessed during zpi+/-ct and eligible patients (depending on age, comorbidities and response criteria) receive allogeneic transplant. patient follow-up is planned for 3 years old


Eligibility criteria:
inclusion criteria: * patient \>18 years old and ≤ 75 years old, with atll-hr who signed informed consent. exclusion criteria: * pregnant or nursing women are not eligible; neither are women of childbearing potential unless using effective contraception as determined by the patient's physician.
safety and efficacy of olopatadine hcl nasal spray in 6-11 year old patients

Conditions: Seasonal Allergic Rhinitis

Summary: a study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.


Eligibility criteria:
inclusion criteria: * male or female; minimum of 6 years of age and less than 12 years * 2 year history of seasonal allergic rhinitis exclusion criteria: * concurrent disease that might interfere with the investigation or evaluation of te study medication * confirmed diagnosis of chronic rhinosinusitis within the last year * asthma, with the exception of mild intermittent asthma * anatomical nasal deformity * nasal obstruction * known non-responder to antihistamines for symptoms of seasonal allergic rhinitis (sar) * chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids * ocular disorder other that allergic conjunctivitis

Keywords: allergic rhinitis allergies seasonal allergies
assessment of er:yag laser for the control of hypersensitivity during tooth whitening with hydrogen peroxide

Conditions: Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity Response

Summary: introduction: tooth whitening is an aesthetic procedure with rapid results that improves the self-esteem and self-image of patients. however, one of the side effects is dentinal hypersensitivity. the aim of the study is to assess the effectiveness of er:yag laser administered prior to bleaching with 35% hydrogen peroxide hypersensitivity. methods: the maxillary arch of participants 18 to 45 years of age will be treated using the split-mouth method. grupo experimental: hypersensitivity prevention protocol with er:yag laser followed by bleaching with 35% hydrogen peroxide; control group: hypersensitivity prevention protocol with neutral sodium fluoride for four minutes followed by bleaching with 35% hydrogen peroxide. er:yag laser (2940 nm) will be used with the following parameters: 0.15 w, 10 mj, 15 hz and sp mode (pulse duration: 300 µs), tip: cylindrical quartz 1000/4, using the h14 handpiece (h14 for lightwalker at; fotona dd, ljubljana, slovenia). each tooth (central incisor, lateral incisor and canine) will be irradiated twice for 10 s in an unfocused scanning motion in the cervical region at a working distance of 1 cm. the absolute risk and intensity of dentinal hypersensitivity during treatment will be assessed using the visual analogue scale. the change in color will be determined using an intraoral spectrophotometer in contact with the tooth. assessments will be conducted before and after preventive treatment, immediately after treatment as well as 48 hours and one week after treatment. different statistical tests will be used, with the significance level set at 5% (p ≤ 0.05).


Eligibility criteria:
inclusion criteria: * all anterior teeth present without caries or restorations; * absence of cervical lesions, dental pain and hypersensitivity prior to treatment; * not having previously undergone any tooth whitening procedure. exclusion criteria: * smokers; * pregnant or nursing women; * individuals with gingivitis or periodontitis, those with enamel cracks detected by the transillumination test; * those with enamel defects or stains caused by tetracycline; * those with systemic diseases; * those taking nonsteroidal anti-inflammatory.
children's acute surgical abdomen programme

Conditions: Children, Only; Surgery; Abdomen, Acute; Perioperative Complication

Summary: to describe the type and quality of care being delivered to children (aged 1 - 16 years old) undergoing emergency abdominal surgery in the united kingdom by measuring baseline compliance against evidence-based recommendations and identifying variations in care between individual hospitals.

the children's acute surgical abdomen programme (casap) is a prospective national observational cohort study which aims to characterise the type and quality of care being delivered to children having emergency abdominal surgery. the investigators aim to recruit every u.k. hospital undertaking this type of surgery in children, and capture information on 5000 patients over the study period. the data collected will include information on patient risk factors, compliance with process quality indicators and the incidence and type of postoperative complications encountered. the data collected will be used to describe the current epidemiology of this patient group and to develop and internally validate a risk prediction tool for children undergoing emergency abdominal surgery. this tool be used to provide hospitals with their own risk-adjusted outcome measures and can subsequently be used to inform bedside decision-making. patients will be followed up for 10 years through a data linkage process with national health service (nhs) digital national databases.

Eligibility criteria:
inclusion criteria: * children aged 12 months and 16 years old * children undergoing unplanned abdominal surgery, where the preoperative diagnosis was considered to be related to a non-traumatic bowel (including appendix), hepatobiliary, and/or splenic pathology. (definitions - unplanned is defined as non-elective (i.e. the patient presented requiring emergency or urgent intervention, either as a primary presentation or as a complication of previous surgery). surgery is defined as a procedure undertaken by a surgeon in an operating theatre requiring the support of an anaesthetist. any surgical approach (e.g. open, laparoscopic, robotic assisted etc) is acceptable.) exclusion criteria: * patients / parents who do not provide consent. * children \<12 months old on day of surgery * elective procedures * operations where the preoperative indication for surgery was considered to be traumatic, urological or gynaecological in origin * organ transplants * insertion/removal of dialysis catheters * interventional radiology procedures * caesarean sections * herniotomies, if the procedure does not involve access to the intra-abdominal cavity.
assessing dna changes in high risk prostate cancer to determine prognosis

Conditions: Prostate Cancer

Summary: one of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. common clinical and pathological parameters are useful (psa, gleason score, etc.) but do not clearly predict who will benefit from treatment and who will fail. genetic markers for tumor aggressivity would be of greater value. the finding that the tmprss2-erg gene fusion is associated with an increase risk of cancer progression is important. tmprss2 is controlled by androgen (testosterone) and erg is part of a family of proteins which have a role in controlling cell growth, cell specialization and producing tumors. as a consequence of this gene fusion, production of the erg protein increases in the presence of testosterone and could be key to the development of prostate cancer, resistance to treatment and poor outcome. the pten gene is known to have a role as a tumor suppressor. its deletion is a contributing factor in the development of prostate cancers and poor outcome. the coexistence of the two markers could be associated with a higher risk of recurrence. to date there have been no studies regarding the presence of either of these two markers or their coexistence in high risk prostate cancer patients who, despite radiation therapy and androgen suppression, develop biochemical failure (their psa levels rise once again). patients participating in the pcs iv study (high risk prostate cancer treated with radiation therapy plus either 18 or 36 months of hormonal suppression) who have had biochemical failure or 3 years of follow-up post hormonal therapy will be approached. tumor blocks from consenting patients will be collected and analyzed for the presence of the tmprss2-erg gene fusion and the pten deletion at the pathology department of the jewish general hospital. statistical analysis will be carried out to see whether either or both markers are present, whether they are associated with certain clinical and pathological high risk factors, and whether they can be used to predict which patients will fail treatment.


Eligibility criteria:
inclusion criteria: * patients with prostate cancer post radical radiation therapy and lhrh agonist treated in pcsiv clinical trial * biochemical failure (psa nadir + 2) or minimum follow-up of 3 years post completion of hormonal therapy * high risk group 1. gleason score 8-10 2. psa ≥ 20 ng/ml 3. t3 or t4

Keywords: biochemical failure hormonal therapy
clinical application of biocleanse meniscus

Conditions: Tear of Meniscus of Knee

Summary: this study will follow patients after routine surgery of a meniscal allograft transplant.

the biocleanse meniscus is available to to all orthopedic surgeons for transplantation. the purpose of this registry is to allow close monitoring of a subgroup of patients receiving the biocleanse meniscus. all patients who have selected a biocleanse meniscus for their meniscal allograft transplant will be asked to join the registry. outcomes will be measured by subjective subject questionnaires as well as x-rays and mri.

Eligibility criteria:
inclusion criteria: * all patients, up to 10 who have selected a biocleanse meniscus transplant exclusion criteria: * anyone not eligible for a meniscal transplant

Keywords: meniscus transplant meniscal allograft mat knee
airway responses to montelukast and desloratadine.

Conditions: Asthma

Summary: montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. this project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.


Eligibility criteria:
inclusion criteria: * baseline fev1 \> or = 65% predicted * positive methacholine challenge (i.e. methacholine pc20 \< or = 16mg/ml * positive allergen challenge exclusion criteria: * negative skin prick test * lung condition/disease other than asthma * currently use montelukast and/or desloratadine
dairy based probiotic intervention and cognitive, emotional, and inflammatory outcomes

Conditions: Cognitive Decline; Cognitive Change; Inflammation; Emotions

Summary: the purpose of this study was to determine the effect of dairy-based probiotics on cognitive function, emotional wellbeing, and inflammation. subjects were assigned to either consume 6 oz of yogurt/day or abstain from consuming yogurt and other probiotic-containing foods for 12 weeks. subjects completed baseline testing and 12-week follow-up testing consisting of a laboratory blood draw to assess inflammatory biomarkers, and a computerized assessment to evaluate cognitive and emotional wellbeing measures.


Eligibility criteria:
inclusion criteria: * ability to participate in a 12-week study * at least 50 years of age * not currently taking a probiotic dietary supplement * willing to refrain from consuming probiotic dietary supplements or fermented foods for 12-weeks * willing to have blood drawn twice * willing to consume yogurt daily for 12 weeks exclusion criteria: -

Keywords: probiotics cognition emotional wellbeing inflammation older adults yogurt
effect of oculomotor and gaze stability exercises on the improvement of balance after stroke

Conditions: Stroke; Distorted; Balance

Summary: individuals older than 60 years old, discharged after suffering brain stroke with referral to the rehabilitation outpatient clinic, will be assessed for orthostatic balance. patients with positive romberg test are invited to participate in the trial. participants will be randomized to either the current rehabilitation protocol or to an supplemental intervention focused on oculomotor and gaze stability exercises to be applied at home for three weeks. participants will be assessed with standardized, validated tools.

the study aims to evaluated the effect of a home program of oculomotor and gaze stability exercises on improvement the balance in stroke patients. individuals older than 60 years old, discharged after suffering brain stroke and referred to the neurologic rehabilitation outpatient clinic, will be assessed for a neuro-motor deficits. patients will be consider eligible if they had positive romberg test (disorder of orthostatic balance) and they will be invited to participate in the trial. patients with previous balance problems will be excluded. participants will be allocated in two intervention groups through block randomization, either the current rehabilitation protocol or to an supplemental intervention focused on oculomotor and gaze stability exercises to be applied at home for three weeks. participants will be assessed with motor assessment scale, berg balance scale and timed up and go test.

Eligibility criteria:
inclusion criteria: * stroke diagnosis 3 to 15 months before recruitment * balance deficits (positive romberg) * patients able to walk 3 meters without assistance with or without an assistive device exclusion criteria: * balance problems previous to the index stroke * severe osteo-articular lesions that compromise the ability to perform the proposed exercises * previous exposure to oculomotor or gaze stability exercises

Keywords: stroke postural balance oculomotor and gaze stability exercises rehabilitation physical therapy outpatient
real world evidence of the effectiveness of paritaprevir/ritonavir (r) - ombitasvir, + dasabuvir without ribavirin in participants with chronic hepatitis c and compensated liver cirrhosis in the russian federation

Conditions: Chronic Hepatitis C

Summary: this prospective, multi-center, observational study is designed to assess the real world effectiveness of paritaprevir/r - ombitasvir with dasabuvir (3daa \[direct-acting antiviral agent\] abbvie regimen) without ribavirin (rbv) and to describe baseline characteristics of participants with chronic hepatitis c virus (hcv) genotype 1b (gt1b) infection and compensated liver cirrhosis in russia.


Eligibility criteria:
inclusion criteria: * 3daa abbvie regimen will be prescribed by physicians according to the routine clinical practice * treatment-naïve or interferon (ifn)/ribavirin (rbv)-experienced participants with confirmed chc gt1b and compensated liver cirrhosis, receiving therapy with the interferon-free 3daa abbvie regimen initiated not earlier than 2 weeks before the enrollment or the initiation is planned not later than 2 weeks after the day of enrollment in accordance to standard of care and in line with the current local label * participants must not be participating or intending to participate in a concurrent interventional therapeutic trial exclusion criteria: * co-administration ribavirin (rbv) with the 3daa abbvie regimen * participants with child pugh b and c cirrhosis * participants with a history of prior direct-acting antiviral agent (daa) therapy * any other contraindications to the administration of 3daa abbvie regimen according to the label

Keywords: paritaprevir dasabuvir ombitasvir ritonavir ribavirin free chronic hepatitis c genotype 1b (gt1b) cirrhosis compensated liver cirrhosis hepatitis
extension study of subcutaneous immunoglobulin human in patients with primary immunodeficiency (pid)

Conditions: Primary Immune Deficiency

Summary: the purpose of this study is to determine whether a long-term use of a new human immunoglobulin g with proline (igpro) is safe and effective in the treatment of primary immunodeficiency.


Eligibility criteria:
inclusion criteria: * subjects with primary humoral immunodeficiency who have participated in the study zlb04_009cr (nct00419341), namely with a diagnosis of common variable immunodeficiency (cvid) as defined by pagid (pan-american group for immunodeficiency) and esid (european society for immunodeficiencies) or x-linked agammaglobulinemia (xla) as defined by pagid and esid * women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening * written informed consent exclusion criteria: * ongoing serious bacterial infection at the time of screening * malignancies of lymphoid cells such as lymphocytic leukemia, non-hodgkin's lymphoma, and immunodeficiency with thymoma * hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration \> 0.2 g/l) * other significant medical conditions that could increase the risk to the patient * females who are pregnant, breast-feeding or planning a pregnancy during the course of the study * a positive result at screening on any of the following viral markers: human immunodeficiency virus (hiv), hepatitis c virus (hcv) or hepatitis b virus (hbv) * aspartate aminotransferase (asat) or alanine aminotransferase (alat) concentration \> 2.5 times upper normal limit (unl) at completion visit of study zlb04_009cr (nct00419341) * creatinine concentration \> 1.5 times unl at completion visit of study zlb04_009cr (nct00419341) * participation in a study with an investigational product other than igpro20 within 3 months prior to enrollment * evidence of uncooperative attitude * any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial * subjects who are employees at the investigational site, relatives or spouse of the investigator

Keywords: cvid xla
effect of connective tissue massage on premenstrual syndrome

Conditions: Premenstrual Syndrome

Summary: this study will be conducted to investigate the effect of connective tissue massage on premenstrual syndrome.

premenstrual syndrome is a collection of emotional, physiological and behavioral symptoms that develop around the end of the luteal phase and fade away with or after mensturation. the physiological effects of connective tissue massage (ctm) are both local and general. local effects include release of histamine from mast cells which leads to a triple response, local swelling and arteriolar dilatation mediated by local axon reflexes. the increased blood flow to the region assists resolution of subacute or chronic inflammation and reduces pain by removing nocigenic chemicals from the tissues. the mechanical distortions produced by ctm strokes help to mobilize connective tissue and improve function. few studies have investigated the effect of the ctm on premenstrual syndrome in adolescent females. so this study will be conducted to add new information about the effect of connective tissue massage on premenstrual syndrome, which may help adolescent females suffering from this syndrome in decreasing their symptoms, thus adding new information to the field of physical therapy.

Eligibility criteria:
inclusion criteria: * virgin adolescent females diagnosed with premenstrual syndrome. * their age will be ranged from 17-25 years (3 years post puberty). * their body mass index (bmi) will be less than 30 kg/m2 . * all are of regular menstrual cycles. * all of them suffering from moderate and severe pms. exclusion criteria: participants will be excluded from this study if they have * any pathological finding in the pelvic cavity as polycystic ovarian syndrome, endometriosis, and pelvic inflammatory diseases. * irregular menstruation. * any history of gynecological intervention. * open wounds, weak/broken bones or fractures.
phase ii study of docetaxel plus cddp for nsclc stage iii

Conditions: NSCLC

Summary: to assess the overall response rate to docetaxel plus cddp as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus cddp in chemonaive patients nsclc stage iiia and iiib.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc, respectable nsclc stage iiia t1-2 n2 or or unresectable stage iiib 2.kps\>70% 3.hb\>10g/dl,anc\>2.0x109/l,plt.\>100x109/l4.t-bil.\ 60 ml/min,gpt/got\<2.5xuln,alp\<5xuln exclusion criteria: * 1.brain meta.2..prior surgery,r/t, c/t or immunotherapy for nsclc
the inform study: rotational fractional resection for submental contouring

Conditions: Skin Laxity

Summary: efficacy and safety of rotational fractional resection (skin resection) in patients with moderate to severe submental skin laxity.

this is a prospective, multi-center, single-arm (non-randomized), interventional cohort, non-significant risk (nsr) study designed to investigate the efficacy and safety of rotational fractional resection (skin resection) in patients with moderate to severe submental skin laxity. the total duration of study participation for each subject is approximately up to 4 months for each subject from the screening visit to the exit visit. the follow-up period will be approximately 3 months after the procedure. eligible subjects will complete a total of 11 study visits: screening, procedure, and follow-up visits at 1, 2-4, 7, 14, 21, 30, 45, 60, and 90 days post-procedure.

Eligibility criteria:
inclusion criteria: * healthy male or female * at least 30 years old * moderate to severe submental laxity * agree to maintain weight (±5%) for the duration of the study exclusion criteria: * greater than mild submental fat * previous intervention to treat submental fat or skin laxity * use of aspirin, ibuprofen, naproxen, or vitamin e within 14 days of the procedure * severe acne, cystic acne or acne scars on neck * trauma of chin or neck area * skin infection or rash on neck * psoriasis, hyperpigmentation, eczema, rosacea or vitiligo * history of scarring * body mass index (bmi) \>30 * clinically significant bleeding disorder * anemia, kidney disease, or liver disease

Keywords: submental laxity